RYTM Q4 2019 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$34M

Net Income

-$33M

EPS (Diluted)

$-0.78

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$309M

Total Liabilities

$28M

Stockholders' Equity

$281M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$34M	-$27M	-26.1%
Net Income	-$33M	-$26M	-29.2%